Dr. Lal PathLabs Limited announced the outcome of its Board Meeting held on November 04, 2026. The board approved the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Additionally, the company declared a 2nd interim dividend of INR 5 per equity share for the financial year 2026-27, with a record date set for November 11, 2026. The appointment of Ms. Vasuta Agarwal as an Additional Director was also approved.
Board Meeting Outcomes
Dr. Lal PathLabs Limited convened a Board Meeting on November 04, 2026, where several key decisions were made concerning the company’s financial performance and strategic direction.
Financial Results Approved
The Board reviewed and approved the un-audited financial results, both on a standalone and consolidated basis, for the quarter and half-year ended September 30, 2026. These results, along with the limited review report from statutory auditors, have been attached as ‘Annexure- A’.
Interim Dividend Declaration
A significant decision for shareholders was the declaration of the 2nd interim dividend for the financial year 2026-27. The dividend amount is set at INR 5 per equity share, representing 50% of the face value of INR 10 per share. The record date for determining the eligibility of shareholders for this dividend is November 11, 2026. The dividend is expected to be paid within 30 days of its declaration.
Appointment of Director
Following a recommendation from the Nomination and Remuneration Committee, the Board approved the appointment of Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director. She has been designated as a Non-Executive Independent Director for a term of three consecutive years, commencing November 04, 2026, subject to member approval via postal ballot. Ms. Agarwal is not debarred from holding such an office.
Further Investment in Subsidiary
The Board also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (‘LPL Dubai’). This investment is intended to meet business and operational requirements, including further investment in its subsidiary, Sunshine Healthcare Limited (‘SHL’) in Ghana. This strategic move aims to bolster the group’s international operations and diagnostic capabilities.
Board Meeting Details
The Board Meeting commenced at 11:49 A.M. (IST) and concluded at 01:20 P.M. (IST) on November 04, 2026.
Source: BSE
